Giuseppe Saglio
Università degli Studi di Torino
H-index: 113
Europe-Italy
Top articles of Giuseppe Saglio
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research | Leukemia | Rüdiger Hehlmann Giuseppe Saglio | 2024/1 |
The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings? | Ibrahim Elmakaty Giuseppe Saglio Murtadha Al-Khabori Abdelrahman Elsayed Basant Elsayed | 2024/2/12 | |
Pyrazolo derivatives as human dihydroorotate dehydrogenase (hdhodh) inhibitors for use as antivirals | 2024/2/1 | ||
Challenges in Management of Pediatric Chronic Myeloid Leukemia (pCML) in the Low-Middle Income Countries (LMICs): Insights from an International CML Foundation (iCMLf) Multi … | Pediatric Hematology and Oncology | Nirmalya Roy Moulik Arlene Harriss-Buchan Giuseppe Saglio Meinolf Suttorp | 2024/1/2 |
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study | Blood | Francesco Cavazzini Isabella Capodanno Maria Cristina Miggiano Cristina Bucelli Sabrina Leonetti Crescenzi | 2023/11/28 |
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study | Frontiers in pharmacology | A Iurlo D Cattaneo D Consonni F Castagnetti MC Miggiano | 2023/3/23 |
CML-076 The Downregulation of Both Large E3 Ubiquitin Ligases, HERC1 and HERC2, is a Common and Unambiguous Feature of Chronic Myeloid Leukemia | Clinical Lymphoma Myeloma and Leukemia | Muhammad Shahzad Ali Zunaira Munir Cristina Panuzzo Nabeel Ashraf Stefano Magnati | 2023/9/1 |
International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic … | Blood | Fabrizio Pane Fausto Castagnetti Alfonso Piciocchi Elisabetta Abruzzese Renato Bassan | 2023/11/28 |
Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the … | Blood | Paola Minetto Fabio Guolo Sara Rosellini Alfonso Piciocchi Giovanni Marconi | 2023/11/28 |
Interferon in chronic myeloid leukaemia: Is it useful for treatment‐free remission? | British Journal of Haematology | Massimo Breccia Giuseppe Saglio | 2023/9 |
Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML … | Blood | Sameen Shahid Muhammad Sabar Abid Jamil Muhammad Abbas Khokar Muhammad Absar | 2023/11/28 |
Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study | Blood | Cristina Bucelli Isabella Capodanno Maria Cristina Miggiano Francesco Cavazzini Sabrina Leonetti Crescenzi | 2023/11/28 |
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML | Cancer | Mario Tiribelli Roberto Latagliata Massimo Breccia Isabella Capodanno Maria Cristina Miggiano | 2023/9/1 |
Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study | Blood | Timothy P Hughes Giuseppe Saglio Jan Geissler Dong-Wook Kim Elza Lomaia | 2023/11/28 |
The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First … | Blood | Valentina Giai Fabio Stagno Tiziana Rosso Fausto Castagnetti Isabella Capodanno | 2023/11/2 |
P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON … | HemaSphere | Paola Minetto Fabio Guolo Sara Rosellini Alfonso Piciocchi Giovanni Marconi | 2023/8/1 |
Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study | Blood | Alessandra Iurlo Massimo Breccia Fabio Stagno Elisabetta Abruzzese Fabrizio Pane | 2023/11/28 |
Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an … | Blood | Fabio Stagno Valentina Giai Patrizia Pregno Gabriele Gugliotta Tiziana Rosso | 2023/11/2 |
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis | Haematologica | Jerald P Radich Matthew Wall Susan Branford Catarina D Campbell Shalini Chaturvedi | 2023/6/6 |
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia | Cell Death & Disease | Mohammad Houshmand Nicoletta Vitale Francesca Orso Alessandro Cignetti Ivan Molineris | 2022/6/30 |
